AstraZeneca’s Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson’s Cancer Drug: Analyst
September 11, 2:31 PM
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients
Bristol Myers Squibb’s Opdivo Plus Yervoy Combo Shows Durable, Long-Term Survival In Lung Cancer Patients
September 11, 2:10 PM
Bristol Myers Squibb & Co (NYSE: BMY) announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with met
Why Is Cancer Focused Microcap Stock AIM ImmunoTech Trading Higher Today?
September 11, 1:58 PM
AIM ImmunoTech Inc (NYSE: AIM) announced that Roswell Park Comprehensive Cancer Center has reported the complete topline data from its Phase 1 study evaluating Ampligen (rintatolimod) as a component of a Chemokine-Modulating (CKM) regimen for the treatment of early-stage triple-
Why Is Blood Cancer Focused Marker Therapeutics Stock Trading Higher Today?
September 11, 1:46 PM
Marker Therapeutics Inc (NASDAQ: MRKR) released the preliminary results of the first participant treated with MT-601, its multi-tumor associated antigen (multiTAA)-specific T cell product targeting 6 TAAs, in the Phase 1 multicenter
ADHD-Focused Cingulate Prices Public Offering, Shares Detailed Pivotal Trial Data
September 11, 1:17 PM
Cingulate Inc (NASDAQ: CING) shares are trading lower after the company priced its $4-million public offering at around 58 cents per share
Gilead’s Breast Cancer Drug Shows Promise When Combined With Merck’s Treatment
September 11, 12:45 PM
Gilead Sciences Inc (NASDAQ: GILD) revealed early data from its open-label, Phase 2 EVOKE-02 study evaluating Trodelvy.
Why’s Going On With EyePoint Pharmaceuticals Stock Today?
September 11, 11:34 AM
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) announced interim masked safety data for its lead product candidate EYP-1901 from its ongoing Phase 2 PAVIA trial of EYP-1901 as a potential nine-month treatment for moderately severe to severe non-proliferative diabetic retinopathy and DAVIO 2 trial as a pot
What’s Going On With AstraZeneca Stock Today?
September 11, 10:35 AM
Shares in European pharmaceutical giant AstraZeneca Plc (NASDAQ: AZN) are down amid speculations swirling around the potential departure of AstraZeneca's Chief Executive, Pascal Soriot.
Crinetics Pharma’s Investigational Candidate Shows Promise In Rare Type Of Hormonal Disorder
September 11, 10:05 AM
On Sunday, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) said its Phase 3 PATHFNDR-1 study evaluating paltusotine met the primary and secondary